1 minute reading time (174 words)

Updates in Myelodysplastic Syndromes: Improving Patient Outcomes With Mikkael Sekeres, MD

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid malignancies that derive from abnormal multipotent progenitor cells and are characterized by bone marrow failure and peripheral blood cytopenias (NCCN, 2021; Garcia-Manero et al, 2021). Survival in MDS ranges from a median of 8.8 years in the lowest-risk patients to as little as 0.8 years in the highest-risk patients (ACS, 2018). Data has shown that clinicians may benefit from education that helps them determine the clinical relevance of the latest advances in MDS treatment (i3 Health, 2021). In this activity, Mikkael Sekeres, MD, MS, will help learners to enhance patients' outcomes by exploring predictive and prognostic markers that can individualize MDS treatment, analyzing the latest safety and efficacy data for emerging MDS therapies, and developing strategies to optimize safety and tolerability for novel MDS treatments.

Related Posts

Copyright © 2022 Oncology Data Advisor. All rights reserved.